Fernandes Peter 4
4 · Bellerophon Therapeutics, Inc. · Filed Dec 13, 2022
Insider Transaction Report
Form 4
Fernandes Peter
Chief Regulatory Officer
Transactions
- Tax Payment
Common Stock
2022-12-09$0.93/sh−9,985$9,287→ 22,515 total - Exercise/Conversion
Common Stock
2022-12-09+32,500→ 32,500 total - Exercise/Conversion
Restricted Stock Units
2022-12-09−32,500→ 32,500 total→ Common Stock (32,500 underlying)
Footnotes (2)
- [F1]Each restricted stock unit represents the contingent right to receive, upon vesting of the unit, one share of Bellerophon common stock.
- [F2]On January 26, 2022, the reporting person was granted 65,000 restricted stock units, 50% vesting on December 9, 2022 and 50% vesting on December 8, 2023, as long as the reporting person remains in the service of Bellerophon through the respective vesting date.